Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol F Lippa

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Alzheimer'S Research & Therapy|October 30, 2020
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trialsJennifer G Goldman, Leah K Forsberg, Bradley F Boeve, et al.
Neurology|November 17, 2025
CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and ProgressionDavid G Coughlin, Lavanya Jain, Maria Khrestian, et al.
Neurology|July 16, 2024
Association of CSF α-Synuclein Seeding Amplification Assay Results With Clinical Features of Possible and Probable Dementia With Lewy BodiesDavid G Coughlin, Karen R MacLeod, John S Middleton, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 6, 2016
Arguing against the proposed definition changes of PDBradley F Boeve, Dennis W Dickson, John E Duda, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 8, 2007
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigreesWilliam E Klunk, Julie C Price, Chester A Mathis, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 23, 2023
ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies ConsortiumLavanya Jain, Maria Khrestian, Shane Formica, et al.
Human Molecular Genetics|May 5, 2012
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseasesGiovanni Coppola, Subashchandrabose Chinnathambi, Jason JiYong Lee, et al.
The Lancet. Neurology|May 5, 2018
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association studyCyril Pottier, Xiaolai Zhou, Ralph B Perkerson, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Alzheimer'S Research & Therapy|October 30, 2020
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trialsJennifer G Goldman, Leah K Forsberg, Bradley F Boeve, et al.
Neurology|November 17, 2025
CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and ProgressionDavid G Coughlin, Lavanya Jain, Maria Khrestian, et al.
Neurology|July 16, 2024
Association of CSF α-Synuclein Seeding Amplification Assay Results With Clinical Features of Possible and Probable Dementia With Lewy BodiesDavid G Coughlin, Karen R MacLeod, John S Middleton, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 6, 2016
Arguing against the proposed definition changes of PDBradley F Boeve, Dennis W Dickson, John E Duda, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 8, 2007
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigreesWilliam E Klunk, Julie C Price, Chester A Mathis, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 23, 2023
ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies ConsortiumLavanya Jain, Maria Khrestian, Shane Formica, et al.
Human Molecular Genetics|May 5, 2012
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseasesGiovanni Coppola, Subashchandrabose Chinnathambi, Jason JiYong Lee, et al.
The Lancet. Neurology|May 5, 2018
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association studyCyril Pottier, Xiaolai Zhou, Ralph B Perkerson, et al.
Pageof 8